AU2011322508A1 - Antibodies for the treatment of HIV - Google Patents

Antibodies for the treatment of HIV Download PDF

Info

Publication number
AU2011322508A1
AU2011322508A1 AU2011322508A AU2011322508A AU2011322508A1 AU 2011322508 A1 AU2011322508 A1 AU 2011322508A1 AU 2011322508 A AU2011322508 A AU 2011322508A AU 2011322508 A AU2011322508 A AU 2011322508A AU 2011322508 A1 AU2011322508 A1 AU 2011322508A1
Authority
AU
Australia
Prior art keywords
antibody
cdr
hiv
seq
cxcr4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2011322508A
Other languages
English (en)
Inventor
Christine Klinguer-Hamour
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/913,300 external-priority patent/US9090686B2/en
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Publication of AU2011322508A1 publication Critical patent/AU2011322508A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
AU2011322508A 2010-10-27 2011-10-27 Antibodies for the treatment of HIV Abandoned AU2011322508A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/913,300 US9090686B2 (en) 2009-04-29 2010-10-27 Antibodies for the treatment of HIV
US12/913,300 2010-10-27
PCT/EP2011/068905 WO2012055980A1 (en) 2010-10-27 2011-10-27 Antibodies for the treatment of hiv

Publications (1)

Publication Number Publication Date
AU2011322508A1 true AU2011322508A1 (en) 2013-05-02

Family

ID=44913256

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011322508A Abandoned AU2011322508A1 (en) 2010-10-27 2011-10-27 Antibodies for the treatment of HIV

Country Status (10)

Country Link
EP (1) EP2632953A1 (ko)
JP (1) JP2014504147A (ko)
KR (1) KR20140009174A (ko)
CN (1) CN103180342A (ko)
AU (1) AU2011322508A1 (ko)
CA (1) CA2814908A1 (ko)
MX (1) MX2013004710A (ko)
RU (1) RU2013122770A (ko)
WO (1) WO2012055980A1 (ko)
ZA (1) ZA201302639B (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014224049B2 (en) * 2013-02-28 2018-11-29 Therabiol, Inc. HIV antigens and antibodies
EP3077417A1 (en) * 2013-12-08 2016-10-12 Peptcell Limited Hiv antigens and antibodies and compositions, methods and uses thereof
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US20050002939A1 (en) * 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
MX2010012435A (es) * 2008-05-14 2011-05-03 Lilly Co Eli Anticuerpos anti-cxcr4.
EP2172485A1 (en) * 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
JP2012158521A (ja) * 2009-04-17 2012-08-23 Kureha Corp 外用剤
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer

Also Published As

Publication number Publication date
WO2012055980A1 (en) 2012-05-03
EP2632953A1 (en) 2013-09-04
CN103180342A (zh) 2013-06-26
KR20140009174A (ko) 2014-01-22
CA2814908A1 (en) 2012-05-03
MX2013004710A (es) 2013-08-29
RU2013122770A (ru) 2014-12-10
ZA201302639B (en) 2013-11-27
JP2014504147A (ja) 2014-02-20

Similar Documents

Publication Publication Date Title
AU2010243526B2 (en) Anti CXCR4 antibodies for the treatment of HIV
JP6936361B2 (ja) ヒト免疫不全ウイルス中和抗体
US20220153837A1 (en) Anti-tigit antibodies and their use as therapeutics and diagnostics
KR20160006168A (ko) 인간화 항-cd134(ox40) 항체 및 이의 용도
KR20140069172A (ko) 항­ｃｄ １３４（ｏｘ４０） 및 이의 용도
JP2021505137A (ja) 悪性ｂ細胞を特異的に認知する抗体またはその抗原結合断片、これを含むキメラ抗原受容体及びその用途
KR20200041835A (ko) 재조합 이중특이적 항체
KR102165934B1 (ko) 악성 b 세포를 특이적으로 인지하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항원 수용체 및 이의 용도
TWI764291B (zh) 抗tigit抗體及使用方法
AU2011322508A1 (en) Antibodies for the treatment of HIV
KR20240014058A (ko) 항-cea 항체 및 항-cd137 다중 특이적 항체 및 사용 방법
AU2022285741A1 (en) Anti-ccr8 antibodies and uses thereof
TWI839395B (zh) 靶向cd137的抗體及其使用方法
WO2021175954A1 (en) Antibodies having specificity for btnl8 and uses thereof
KR20240026496A (ko) 항-넥틴4 항체 및 이를 포함하는 다중특이적 단백질 복합체

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted